NMDA receptors have been implicated in the acute response to stress, possibly mediated the nitric oxide pathway; serotonin has also been implicated in these responses, and has recently been shown to modulate the nitric oxide pathway via 5-HT 1 and 5-HT 2 receptors. In this work, we compare the effects of NMDA and a 5-HT 1A receptor ligands on light/dark preference in adult zebrafish, and investigate whether nitric oxide mediates the effects of such drugs. The noncompetitive NMDA receptor antagonist MK-801 decreased dark preference (scototaxis), while NMDA increased it; the effects of NMDA were completely blocked by pretreatment with the nitric oxide synthase (NOS) antagonist L-NAME. SNP, a nitric oxide donor, produced a bell-shaped dose-response profile on scototaxis. Treatment with 5-HTP increased scototaxis, an effect which was potentiated by pre-treatment with NMDA, but not MK-801, and partially blocked by L-NAME. The 5-HT 1A receptor antagonist WAY 100,635 decreased scototaxis, an effect which was completely blocked by L-NAME. These results suggest that tonic NOS inhibition is an important downstream effector of 5-HT 1A receptors in the regulation of dark preference behavior in zebrafish, and that NOS is also under phasic independent control by NMDA receptors.
Introduction
Glutamate has been implicated in the acute response to stress (Hamane et al., 2009; Harvey, 2006; Lupinsky et al., 2010; Reznikov et al., 2007) as well as in the expression of defensive behavior (Yilmazer-Hanke et al., 2003) . Glutamate exerts its actions in the central nervous system through metabotropic and ionotropic receptors; among the latter, the N-methyl-D-aspartate (NMDA) receptor is among the most studied. The NMDA receptor gates inward sodium and calcium currents, and the influx of calcium into the cell leads to the activation of a calcium-dependent isoform of nitric oxide synthase (NOS) and, consequently to the activation of the nitric oxide-cyclic guanosine monophosphate (cGMP) pathway (Garthwaite, 2008) . Nitric oxideproducing cells are enriched in regions of the limbic system which organize defensive behavior in mammals (Matsushita et al., 2001; Simpson et al., 2003; Vincent and Kimura, 1992; Wang et al., 1995) , amphibians (López et al., 2005) and fish (Bordieri et al., 2005; Giraldez-Perez et al., 2008; Holmqvist et al., 2007 Holmqvist et al., , 2000 Virgili et al., 2001) . In rodents, nitrergic neurons are activated after exposure to anxiogenic contexts (Beijamini and Guimarães, 2006) , restraint stress (De Oliveira et al., 2000) , or ethanol withdrawal (Bonassoli et al., 2011) . Systemically, treatment with NOS inhibitors is anxiolytic in the elevated T-maze (Calixto et al., 2001) , in the staircase test (Pokk and Väli, 2002) and in the inhibitory avoidance test (Akar et al., 2007) .
There are some evidences that the nitrergic system interacts with serotonin (5-HT), an important mediator of defensive behavior across species (Maximino, 2012) . The raphe nuclei, sites of origin of serotonergic innervation in the central nervous system, project nitrergic fibers to many different sites (Lu et al., 2010; Okere and Waterhouse, 2006; Simpson et al., 2003; Wang et al., 1995) . Microinjection of NO inhibitors in the raphe blocks the local NMDA-induced 5-HT release (Smith and Whitton, 2000) , prevents the effects of inescapable stress on escape responding and conditioned fear (i.e., learned helplessness) (Grahn et al., 2000) and has a biphasic effect in the Porsolt forced swim test and in the elevated plus-maze (Spiacci Jr et al., 2008) . Microinjection of peroxynitrite donors, on the other hand, increases locomotor activity, an effect which is blocked by pre-treatment with the 5-HT 1A receptor agonist 8-OH-DPAT (Gualda et al., 2011) . The relationship is bilateral, as the activation of 5-HT 1A receptors in neocortex (Maura et al., 2000) or hippocampal (Strosznajder et al., 1996) slices reduces glutamateevoked NO production. In cultured hippocampal neurons, treatment with 5-HT or 8-OH-DPAT downregulates NOS protein expression, an effect which is blocked by treatment with the 5-HT 1A R antagonist NAN-190 (Zhang et al., 2010) ; in the hippocampus of mice treated with 8-OH-DPAT for 3 days, NOS-1 mRNA is downregulated, and NAN-190 increases NOS-1 mRNA by itself (Zhang et al., 2010) . Interestingly, in NOS-1 knockout mice, the anxiolytic effect of chronic 8-OH-DPAT treatment is absent, and pre-treatment with the NOS inhibitor 7-NI blocks the anxiogenic effect of NAN-190 microinjected in the hippocampi of wild-type animals (Zhang et al., 2010) .
Zebrafish (Danio rerio Hamilton 1822) have recently been introduced in the field of behavioral neuroscience and biological psychiatry (Gerlai, 2010; Norton and Bally-cuif, 2010) , especially in the field of stress and anxiety research (Jesuthasan, 2011; Kalueff et al., 2012; Maximino et al., 2010b; Steenbergen et al., 2011; Stewart et al., 2011) . The serotonergic system of this teleost is relatively conserved (Lillesaar, 2011; Maximino et al., 2013a) , although some differences exist such as the duplication genes encoding synthetic enzymes, receptors and transporters (Bellipanni et al., 2002; Norton et al., 2008; Wang et al., 2006) , the existence of a single copy of monoamine oxidase (Anichtchik et al., 2006) , and nuclei outside the raphe (Kaslin and Panula, 2001) . Nonetheless, the pharmacology of the serotonergic system seems to be rather conserved (Maximino and Herculano, 2010; Stewart et al., 2013) . We have previously demonstrated that the 5-HT 1A partial agonist buspirone and the antagonist WAY 100,635 have anxiolytic-like effects in the light/dark and in the novel tank tests (Maximino et al., 2013b (Maximino et al., , 2011 . In this article, we investigate whether the nitrergic system mediates some of these behavioral effects.
Materials and methods

Animals
247 adult (~4 month) unsexed zebrafish from the striped longfin wild-type phenotype were acquired in a local pet shop and used in the present experiments. Animals were group-housed in 40 L tanks, with a maximum density of 25 fish per tank, for at least 2 weeks before experiments begun. Tanks were filled with deionized and reconstituted water at room temperature (28°C) and a pH of 7.0-8.0. Lighting was provided by fluorescent lamps in a cycle of 14-10 h (LD), according to the standard of care zebrafish (Lawrence, 2007) . All manipulations minimized their potential suffering, as per the recommendations of the Canadian Council on Animal Care (Canadian Council on Animal Care, 2005). All procedures complied with the Brazilian Society for Neuroscience and Behavior's (SBNeC) guidelines for the care and use of animals in research.
Drugs
All drugs were bought from Sigma-Aldrich (St Louis, MO, USA), dissolved in Cortland's salt solution (Wolf, 1963) , and injected intraperitoneally in cold-anesthetized animals (Kinkel et al., 2010) . To provide a picture of the role of NMDA receptors in zebrafish anxiety-like behavior, NMDA (0 and 0.011 mg/kg; n = 6 per group) and MK-801 (0, 0.2 and 2.0 mg/kg; n = 10 per group) were used to activate and block the receptor, respectively. The role of NOS as a downstream effector of NMDA was tested by pre-treating animals with the NOS inhibitor L-NAME (0 and 5.0 mg/kg; n = 6 per group) before NMDA injection. The role of NO was further analyzed by injecting animals with the NO donor sodium nitroprusside (SNP, 0.5-10 mg/kg; n = 6-7 per group). Serotonergic tonus was increased by injecting the precursor 5-HTP (0 and 300 mg/kg; n = 9-10 per group); the interaction between 5-HT and the glutamate-NMDA pathway was analyzed by pre-treating 5-HTP-injected animals with either NMDA (0 and 0.011 mg/kg; n = 10 per group) or MK-801 (0 and 0.2 mg/kg; n = 10 per group). To analyze the mediation of NOS in the effects of 5-HTP, animals were pre-treated with L-NAME (0 and 5.0 mg/kg; n = 9 per group). To understand the role of 5-HT 1A receptors, the antagonist WAY 100,635 (0 and 0.03 mg/kg; n = 8-9 per group) was injected; finally, the mediation of NOS on the effects of WAY 100,635 was analyzed by pre-treating animals with L-NAME (5.0 mg/kg). With the exception of WAY 100,635 and 5-HTP, which were tested at these doses in zebrafish (Maximino et al., 2013b; Herculano and Maximino, 2014) , all doses were based on rodent literature (Olney et al., 1979; Plaznik et al., 1994; Calixto et al., 2001 ).
Light/dark preference
The light/dark preference test analyzes zebrafish exploratory behavior under motivational conflict, as opposed to escape as has been proposed in the novel tank test . In addition, the effects of serotonergic (Maximino et al., 2013b and glutamatergic agents have been described in this test. Thus, determination of drug effects on scototaxis was carried as described elsewhere (Araujo et al., 2012; Maximino et al., 2010a) . Briefly, 30 min after drug injection animals were transferred to the central compartment of a black and white tank (15 cm × 10 cm × 45 cm h × d × l) for a 3-min acclimation period, after which the doors which delimit this compartment were removed and the animal was allowed to freely explore the apparatus for 15 min. The following variables were manually recorded by an observer blind to treatment: time on the white compartment: the time spent in the white portion of the tank (percentage of the trial); squares crossed: the number of 10 cm 2 squares crossed by the animal in the white compartment; latency to white: the amount of time the animal spends in the black compartment before its first entry in the white compartment(s); entries in white compartment: the number of entries the animal makes in the white compartment in the whole session; erratic swimming: the number of "erratic swimming" events, defined as a zig-zag, fast, and unpredictable course of swimming of short duration; freezing: the proportional duration of freezing events (in % of time in the white compartment), defined as complete cessation of movements with the exception of eye and operculae movements; thigmotaxis: the proportional duration of thigmotaxis events (in % of time in the white compartment), defined as swimming in a distance of 2 cm or less from the white compartment's walls; and risk assessment: the number of "risk assessment" events, defined as a fast (b 1 s) entry in the white compartment followed by re-entry in the black compartment, or as a partial entry in the white compartment (i.e., the pectoral fin does not cross the midline).
Statistical analysis
Drug effects on behavioral parameters were analyzed using one-way parametric or non-parametric (Kruskal-Wallis) analyses of variance followed by Tukey's HSD post-hoc tests whenever appropriate. Results from these statistical analyses were considered significant when p b 0.05. Latency outcomes were analyzed by log-rank Mantel-Cox tests based on survival curves (Jahn-Eimermacher et al., 2011), with α for multiple comparisons adjusted by the Bonferroni method.
Results
NMDA ligands alter behavior in the light/dark test in a NOS-dependent way
Treatment with 0.2 mg/kg, but not 2.0 mg/kg, MK-801 increased the time spent on the white compartment (F 2, 29 = 11.34, p = 0.0003; Fig. 1A ). The highest dose increased the number of entries in the white compartment (F 2, 29 = 32.82, p b 0.0001; Fig. 1C ) and decreased thigmotaxis (Fig. 1G) . No other effects were observed. Treatment with 0.011 mg/kg NMDA decreased the time spent in the white compartment, an effect which was abolished by pre-treatment with L-NAME in a dose which was by itself ineffective (F 3, 23 = 33.13, p b 0.0001; Fig. 2A) ; moreover, NMDA impaired white avoidance habituation, an effect which again was blocked by pre-treatment with L-NAME (F 3, 23 = 3.811, p = 0.0261; Fig. 2B ). NMDA, L-NAME or both drugs did not alter the latency to enter the white compartment Fig. 2H ), and the duration of freezing events (F 3, 23 = 9.404, p = 0.0004; Fig. 2F ) and thigmotaxis (F 3, 23 = 6.5, p = 0.003; Fig. 2G) ; in all cases, L-NAME pre-treatment blocked the effects of NMDA.
A nitric oxide donor produces biphasic effects on scototaxis
To further understand the role of nitric oxide on the control of anxiety-like behavior, we administered sodium nitroprusside (SNP), a nitric oxide donor, in five doses (from 0.5 to 10 mg/kg) in zebrafish and recorded their behavior in the light/dark test. SNP increased the time on white at 1 and 5 mg/kg, and decreased it at 10 m/kg (F[ 5, 39] = 30.65, p b 0.0001; Fig. 3A) ; these effects approached a bell-shaped curve when log dose-response was analyzed (unweighted r 2 = 0.8526). No effects were observed on the total locomotion in the dose range analyzed (F [5, 40] = 1.224, p = 0.3188; Fig. 3B ).
Synergism between 5-HTP and NMDA treatments in scototaxis
Treatment with 5-HTP (300 mg/kg) decreased time on white, an effect which was potentiated by pre-treatment with NMDA (F [2, 54] = 15.78, p b 0.0001 for the interaction term; Fig. 4A ). Pre-treatment with MK-801, however, did not alter the effect of 5-HTP on scototaxiscontrary to what happened with pre-treatment with L-NAME, which partially blocked the effect of 5-HTP on scototaxis (F [1, 32] = 3.417, p = 0.05; Fig. 4B ). These results suggest that the activation of 5-HT receptors increases scototaxis, an effect which is potentiated, but not dependent on, activation of the NMDA receptor; moreover, these effects are dependent on the activation of nitric oxide synthase. Fig. 5C ). While WAY 100,635 by itself had no effect on thigmotaxis, pre-treatment with L-NAME plus the highest dose of the 5-HT 1A R antagonist decreased it (F 4, 39 = 3.093, p = 0.0279; Fig. 5G ). No effect was observed on freezing (F 4, 39 = 0.1335, p = 0.969; Fig. 5F ) nor on erratic swimming (H [df = 5] = 4.077, p = 0.3957; Fig. 5E ). The highest dose decreased risk assessment, an effect which was blocked by L-NAME (H [df = 5] = 11.87, p = 0.0183; Fig. 5H ).
Discussion
In the present work, NMDA was found to increase scototaxis, impaired habituation, and increased erratic swimming, risk assessment, freezing and thigmotaxis in the light/dark tank -effects which were blocked by pre-treatment with a NOS antagonist, L-NAME; treatment with the NMDA non-competitive antagonist MK-801 decreased scototaxis, but did not alter other variables. Similarly, treatment of rodents with MK-801 showed an anti-conflict effect and reduced thigmotaxis in an open-field (Plaznik et al., 1994) , while in the plus-maze another non-competitive antagonist is ineffective (Wiley et al., 1995) . In zebrafish, MK-801 has been shown to not alter light/dark preference (Sison and Gerlai, 2011) , although the preference task used differed significantly from that presented here in that the light side is actually a transparent, well-lit portion, while the dark side is covered from the top; in this configuration, animals tend to prefer the light side, instead of the dark one (Blaser and Peñalosa, 2011; Gerlai et al., 2000) , and thus comparison of these results with ours is limited. In zebrafish, MK-801 has also been shown to produce hyperactivity (Sison and Gerlai, 2011) and to block habituation of the acoustic startle response (Best et al., 2008; Roberts et al., 2011) . Other drugs with antiglutamatergic effects have been shown to affect zebrafish behavior. Most extensively used were drugs with psychotomimetic effects (kynurenic acid, ketamine, MK-801, ibogaine; phencyclidine; Neelkantan et al., 2013) with a polypharmaceutical profile which includes but is not limited to glutamate. In general, these drugs produce an anxiolytic-like profile in different tests that is also accompanied by dissociative-like behavior, suggesting nonspecific effects on anxiety. Nonetheless, MK-801 effects on the light/dark test, as well as the NMDA experiments reported in this paper, suggest that activation of this receptor increases anxiety-like behavior, an effect mediated by nitric oxide production.
Previous work showed that freezing and thigmotaxis are higher in the black compartment of a light/dark tank (Blaser et al., 2010; Blaser and Peñalosa, 2011) , there is no evidence so far that these variables are increased/decreased by anxiolytic-like and anxiogenic-like treatments. Indeed, Blaser and Peñalosa (2011) did not observe changes in freezing or thigmotaxis in black after ethanol treatment. On the other hand, freezing and/or thigmotaxis on white have been repeatedly shown to be altered by drug treatments (e.g., Maximino et al., 2013b Maximino et al., , 2014 . The same was observed in the present experiments regarding the effects of NMDA. While this might represent a methodological limitation of the present work, these observations also suggest that freezing and thigmotaxis in the white compartment are qualitatively different from these behaviors in the black compartment and might be controlled by different behavioral states. Further experiments are necessary to disentangle this hypothesis.
Nonetheless, stimulation of NO targets with the donor SNP produced a biphasic effect on scototaxis -that is, small and intermediate doses increase scototaxis, while intermediate doses decrease it. Biphasic effects of NO donors were observed on 5-HT release in hypothalamic slices (Kaehler et al., 1999) , and 8-Br-cGMP also affects 5-HT uptake in midbrain synaptosomes in a biphasic manner (Ramamoorthy et al., 2007) . Low doses of L-NAME increase open arm exploration in the elevated plus-maze and decrease immobility in the forced swim test in rats, while high doses decrease locomotor activity (Spiacci Jr et al., 2008) . These results seem to suggest that the mediation of the nitrergic system on behavior or on the serotonergic system is complex, depending on the basal and stimulated levels of nitric oxide.
Consistent with these observations, we observed that treatment with the 5-HT precursor 5-HTP increased scototaxis, an effect which was potentiated by pre-treatment with NMDA and partially blocked by pre-treatment with L-NAME. Nonetheless, pre-treatment with MK-801 was unable to change this effect, suggesting that either activation of a different site in the NMDA receptor (the orthosteric site) is needed for synergism with 5-HTP, or that the effects of 5-HTP were mediated by nitric oxide downstream of the NMDA receptor. In consonance with this proposal, in cortical or hippocampal slices, the activation of 5-HT 1A receptors reduces glutamate-evoked NO production (Maura et al., 2000; Strosznajder et al., 1996) .
Previous experiments in zebrafish demonstrated that WAY 100,635 by itself produced an anxiolytic-like effect in both the novel tank and the light/dark tests (Maximino et al., 2013b) . More interestingly, pretreatment with L-NAME completely blocked the effects of WAY 100,635 on scototaxis and risk assessment, suggesting that nitric oxide might be involved in the mechanism of action of this drug. Combined with the previous observations, these results suggest that 5-HT 1A receptors (blocked by WAY 100,635) tonically inhibit nitric oxide production; the removal of this tonic inhibition would increase NO levels in small increments (as observed in rodent cortical or hippocampal slices; Maura et al., 2000; Strosznajder et al., 1996) , decreasing scototaxis and risk assessment. NMDA receptor activation, on the other hand, can directly activate NOS, effectively overriding the tonic inhibition and increasing intracellular NO production to levels which increase scototaxis and risk assessment, as well as fear-like behaviors such as erratic swimming, freezing and thigmotaxis. Therefore, NOS could act as a "switch" to signal the balance of serotonergic and glutamatergic input to post-synaptic structures associated with defensive behavior.
The present results suggest that tonic NOS-1 inhibition is an important downstream effector of 5-HT 1A receptors in the regulation of anxiety-like behavior, and that NOS-1 is also under phasic independent control by NMDA receptors; however, the precise mechanisms by which these receptors interact to regulate anxiety-like behavior is still unclear, and further experiments are necessary to untangle concurrent hypotheses.
